Lakefront Biotherapeutics NV (LKFT) stock
LKFTNasdaqPharmaceutical PreparationsAlso trades as GLPGF
Financials through fiscal 2025, year ended Dec 31, 2025Score 7/30
$34.07−0.32 (-0.93%)
Close on Nov 18, 2026Market cap $2.25BP/E 6.3Yield –
Lakefront Biotherapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
For fiscal 2025 it was €1.11B, up 303.5% from the year before. Over ten years it grew 39.6% a year on average. The highest annual figure on record is €1.11B in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €1.11B | +303.5% |
| FY2024 | Dec 31, 2024 | €275.65M | +15.0% |
| FY2023 | Dec 31, 2023 | €239.72M | -0.6% |
| FY2022 | Dec 31, 2022 | €241.25M | +2.9% |
| FY2021 | Dec 31, 2021 | €234.38M | -51.0% |
| FY2020 | Dec 31, 2020 | €478.05M | -42.7% |
| FY2019 | Dec 31, 2019 | €834.90M | +199.6% |
| FY2018 | Dec 31, 2018 | €278.67M | +119.3% |
| FY2017 | Dec 31, 2017 | €127.09M | -1.9% |
| FY2016 | Dec 31, 2016 | €129.52M | +227.4% |
| FY2015 | Dec 31, 2015 | €39.56M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2021 | Jun 30, 2021 | €139.77M | +419.0% |
| Q2 FY2020 | Jun 30, 2020 | €99.59M | – |
| Q2 FY2019 | Jun 30, 2019 | €58.74M | – |
| Q2 FY2018 | Jun 30, 2018 | €49.68M | – |
| Q2 FY2017 | Jun 30, 2017 | €26.93M | – |
See a number that looks wrong?